At the completion of the trial, she was screened with magnetic resonance imaging (MRI), Tau and β-amyloid positron emission tomography (PET) scans, which supported the diagnosis of Alzheimer’s disease, and she was enrolled in the open-label extension, which guaranteed treatment with the active drug. Here, MAPT is linked to early-onset autosomal dominant Alzheimer disease.